Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A pretargeted imaging strategy based on the HaloTag dehalogenase enzyme is described. Here, a HaloTag-Trastuzumab conjugate has been used as the primary agent targeting HER2 expression, and three new radiolabelled HaloTag ligands have been used as secondary agents, two of which offer dual-modality (SPECT/optical) imaging capability.

Original publication

DOI

10.1039/c4cc10265g

Type

Journal article

Journal

Chem Commun (Camb)

Publication Date

07/03/2015

Volume

51

Pages

4055 - 4058

Keywords

Antibodies, Monoclonal, Humanized, Cell Line, Tumor, Halogens, Humans, Hydrolases, Ligands, Optical Imaging, Tomography, Emission-Computed, Single-Photon, Trastuzumab